GOLGA3

Golgin subfamily A member 3 · Q08378 · GOLGA3 on Sugi Atlas →

0 patent compounds predicted against GOLGA3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to GOLGA3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease PHASE4COMPLETED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD PHASE3COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Ambroxol as a Treatment for Parkinson's Disease Dementia PHASE2UNKNOWN
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma PHASE1/PHASE2NOT_YET_RECRUITING
Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease PHASE1/PHASE2UNKNOWN
Defining Clinical Endpoints in Limb Girdle Muscular Dystrophy (LGMD) nanCOMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy nanUNKNOWN
A Multicenter Phenotype-Genotype Analysis of LGMD Patients in China nanENROLLING_BY_INVITATION
Registry Gangliosidoses nanUNKNOWN
GNAO1 Natural History Study nanUNKNOWN
Biomarker Analysis for GBA Associated Parkinson's Disease nanUNKNOWN
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Genetic Analysis of Gray Platelet Syndrome nanCOMPLETED
Genetic Investigations in Children With Developmental and Epileptic Encephalopathies in Ho Chi Minh City, Vietnam nanUNKNOWN
Canadian Fabry Disease Initiative (CFDI) National Registry nanRECRUITING
Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease nanENROLLING_BY_INVITATION
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
Screening of Fabry Disease in Patients With GI Symptoms nanUNKNOWN
Genetic Studies of Lysosomal Storage Disorders nanENROLLING_BY_INVITATION
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study nanRECRUITING
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) nanCOMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
Clinical Trial Readiness for the Dystroglycanopathies nanRECRUITING
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing nanCOMPLETED
Decoding the Genetic Landscape of Skeletal Diseases nanRECRUITING
Risk Factors for the Development of Celiac Disease in Genetically Predisposed Children nanUNKNOWN
Patient-derived Glioma Stem Cell Organoids nanACTIVE_NOT_RECRUITING
Genetic Study of Patients With Primary Ciliary Dyskinesia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GOLGA3 binder may also engage these)

ProteinNameSimilarity
P55937 0.998 P55937 →
Q9CZX2 0.996 Q9CZX2 →
Q96ST8 0.995 Q96ST8 →
Q2TAC2 0.995 Q2TAC2 →
Q8VDC1 0.993 Q8VDC1 →
Q8CJ40 0.993 Q8CJ40 →
Q6PCQ0 0.992 Q6PCQ0 →
Q9ULE4 0.992 Q9ULE4 →
Q8CFC9 0.992 Q8CFC9 →
P60853 0.992 P60853 →
Q8K2I2 0.992 Q8K2I2 →
B9V5F5 0.992 B9V5F5 →
Q6AW69 0.992 Q6AW69 →
Q6ZU80 0.992 Q6ZU80 →
Q86SQ7 0.991 Q86SQ7 →
F6XLV1 0.991 F6XLV1 →
B8JK76 0.991 B8JK76 →
IKBKG NF-kappa-B essential modulator 0.991 landscape →
A7YH32 0.991 A7YH32 →
Q0KK56 0.991 Q0KK56 →
A6QNP9 0.991 A6QNP9 →
Q6NZW0 0.990 Q6NZW0 →
A0JNT9 0.990 A0JNT9 →
Q5U3A8 0.990 Q5U3A8 →
E7F5E1 0.990 E7F5E1 →
Q9BV73 0.990 Q9BV73 →
Q8HZ57 0.990 Q8HZ57 →
Q8TD31 0.990 Q8TD31 →
Q6P2H3 0.990 Q6P2H3 →
Q29RS0 0.990 Q29RS0 →